e (#	PALM	INTRA	
The state of the s			

Day : Tuesday Date: 4/24/2007

Time: 13:42:43

Inventor Information for 10/517391

Inventor Name	City	State/Country
BASTIEN, PHILIPPE	CHARENTON LE PONT	FRANCE
JOURDAIN, ROLAND	MEUDON LA FORET	FRANCE
DE LACHARRIERE, OLIVIER	PARIS ·	FRANCE
Search Another: Application#	Atty//Agent Info Continu	Search
PCT / /	or PG PUBS #	Search
Attorney Docket #	# Search	

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

Bar Code #

US	US-	20070426	Methods and kits for	435/6		De Lacharriere;
20070092894 A1	PGPUB		detecting single nucleotide polymorphisms of chromosome implicated in premature canities			Olivier et al.
US 20070065389 A1	US- PGPUB	20070322	Genes from chromosomes 3, 5 and 11 involved in premature canities	424/70.13	435/6; 514/44	De Lacharriere; Olivier et al.
US 20070012320 A1	US- PGPUB	20070118	Hair loss questionnaire system and method	128/898	705/3	De Lacharriere; Olivier et al.
US 20060122465 A1	US- PGPUB	20060608	Methods and systems for generating diagnostic algorithms based on questionnaires	600/300	128/920	Bastien; Philippe et al.
US 20060008453 A1	US- PGPUB	20060112	Methods and compositions for preventing and treating sensitive and dry skin	424/93.45		Breton; Lionel et al.
US 20050214821 A1	US- PGPUB	20050929	Chromosome 6 and 9 genes involved in premature canities	435/6	424/70.13	De Lacharriere, Olivier et al.
US 20050208010 A1	US- PGPUB	20050922	Genes from Chromosome 3, 5 and 11 involved in premature canities	424/70.13	514/44	De Lacharriere, Olivier et al.
US 20040116824 A1	US- PGPUB	20040617	Evaluation or diagnostic kit	600/556	424/9.2	Hirt, Jean-Pascal et al.
US 20040037776 A1	US- PGPUB	20040226	Non-therapeutic methods of evaluating skin neurosensitivity, kit and use of a kit for implementing the method	424/9.81		Lacharriere, Olivier De et al.
US 20040034610 A1	US- PGPUB	20040219	Methods involving artificial intelligence	706/20	706/25; 707/101	De Lacharriere, Olivier et al.
US 20030124084 A1	US- PGPUB	20030703	Use of dehydroepiandrosterone and/or precursors or derivatives thereof to improve papery aspect of the skin	424/74	424/757; 424/773; 514/178	De Lacharriere, Olivier et al.
US 20030064929 A1	US- PGPUB	20030403	Modulating body/cranial hair growth	514/12	424/70.122; 424/70.14; 435/192; 530/324	Duranton, Albert et al.
US	US-	20030227	Use of a composition	424/401	514/55;	De Lacharriere,

•

20030039669	PGPUB		containing an effective	·	514/6	Olivier et al.
A1			quantity of at least one chelating agent for		317/0	Olivioi et al.
~			partially or totally reducing the symptoms	ĺ		
			associated with histamine release in the organism			
US 20030026820 A1	US- PGPUB	20030206	Use of a compositon containing an effective quantity of at least one ion chelating agent for	424/401	514/6	De Lacharriere, Olivier et al.
			increasing the tolerance threshold of a sensitive or intolerant skin			
US 20020068072 A1	US- PGPUB	20020606	USE OF A SUBSTANCE P ANTAGONIST IN A PHARMACEUTICAL COMPOSITION	424/401	424/400	DE LACHARRIERE, OLIVIER et al.
US 20020037854 A1	US- PGPUB	20020328	USE OF AT LEAST ONE NO SYNTHASE INHIBITOR FOR TREATING SENSITIVE SKIN	514/18	514/19; 562/560	BRETON, LIONEL et al.
US 20010051157 A1	US- PGPUB	20011213	THERAPEUTIC/COSME TIC COMPOSITIONS COMPRISING CGRP ANTAGONISTS FOR TREATING SENSITIVE HUMAN SKIN	424/133.1	424/130.1; 424/158.1; 424/809; 514/2; 530/300; 530/387.1	BRETON, LIONEL et al.
US 20010028889 A1	US- PGPUB	20011011	Therapeutic/cosmetic compositions comprising bradykinin antagonists for treating sensitive human skin	424/401		Breton, Lionel et al.
US 6572848 B1	USPAT	20030603	Use of a substance agonist of a receptor associated with a chlorine or potassium canal for treating sensitive skins	424/78.02	424/401; 424/78.05; 424/78.07; 514/221; 514/275;	Breton; Lionel et al.
					514/302; 514/353; 514/354; 514/355;	
					514/356; 514/561; 514/711; 514/864; 514/887	

US 6509014	USPAT	20030121	Therapeutic/cosmetic	424/130.1	514/2;	De Lacharriere;
B1			compositions comprising CGRP antagonists for		530/300; 530/350;	Olivier et al.
			treating skin		530/387.1	
			redness/rosacea/discreet			13
			erythema			
US 6471997	USPAT	20021029	Iridaceae extract and	424/725	424/773;	Breton; Lionel e
B1			compositions containing it		424/774;	al.
	TIOD : T	20021015			424/779	
US 6465421	USPAT	20021015	Modulating body/cranial	514/1	424/70.1;	Duranton; Alber
B1			hair growth		514/169;	et al.
			·		514/712;	
					514/715;	-0,0
					514/717;	
					514/880; 548/100;	•
					554/1;	
					562/400	
US 6416760	USPAT	20020709	Therapeutic/cosmetic	424/185.1	424/130.1;	Breton; Lionel e
B2			compositions comprising	, 10011	424/133.1;	al.
· .			CGRP antagonists for		424/145.1;	
			treating sensitive human		424/158.1;	
	_6		skin		424/198.1;	
					514/2;	
		91 19			530/300;	
~	550.05	. Attitition	-5		530/387.1	
US 6344438	USPAT	20020205	Therapeutic/cosmetic	514/2	514/844	De Lacharriere;
B1	1		compositions comprising			Olivier et al.
			CGRP antagonists for			
			treating the eyes or	,		
110 (077007	LICDAT	20010921	Use of a histamine	424/401	424/70 1	De Laster
US 6277387 B1	USPAT	20010821	antagonist, an interleukin-	424/401	424/70.1; 514/844;	De Lacharriere; Olivier et al.
וע			1 antagonist and/or a TNF		514/859;	Onvier et al.
			alpha.antagonist in a		514/937;	
			cosmetic, pharmaceutical		514/944	
			or dermatological			
			composition and	·		
			composition obtained		*-	
US 6267972	USPAT	20010731	Cosmetic/pharmaceutical	424/401	424/45;	Breton; Lionel
B1			compositions comprising		424/450;	al.□
•			.betaadrenergic		424/451;	
•		}	agonists/substance P		424/464;	
		,	antagonists		424/489;	
					424/49;	
					424/62;	
					424/65;	
		1	i	1	424/70.1;	

				•		
-					424/73;	
	!	1'			514/844	·
US 6262050	USPAT	20010717	Topical composition	514/213.0		De Lacharriere;
B1	· /	1	containing capsazepine	1		Olivier
US 6241993	USPAT	20010605	Therapeutic/cosmetic	424/401	424/43;	Breton; Lionel et
B1		1	compositions comprising		424/489;	al.
_	'	1 '	bradykinin antagonists for	· .	424/49;	
	!	1 '	treating sensitive human		424/70.1;	
	'	1 '	skin		514/844;	
	'	1 '			514/846;	· ·
	'	1	1		514/936;	
		1	1		514/944	
US 6169069	USPAT	20010102	Therapeutic/cosmetic	514/2	514/844	De Lacharriere;
B1		20010102	compositions comprising	311,2	31 1/311	Olivier et al.
:	'	1	CGRP antagonists for			Onvior et al.
	'	1	treating the eyes or			
	'	1	eyelids	1		
US 6168809	USPAT	20010102	Alkaline-earth metal salt	424/677	424/665;	De Lacharriere;
B1	USPAL	20010102	for the treatment of ocular	424/077	514/912	Olivier et al.
Ві	1	'		.	314/312	Olivier et al.
	·	'	or palpebral pruritus and dysesthesia			
US 6106846	USPAT	20000822	Use of at least one	424/401	424/49;	Proton: Lional at
	USPAL	20000022		424/401	1	Breton; Lionel et al.
A	1	1	thermal spring water from		424/70.1;	ai.
	,	1	Vichy as a substance P	*	514/844;	
	1	1	antagonist		514/846;	
		1	1		514/886;	
		'			514/887;	
	. !	1			514/912;	
					514/937;	•
		22222411		714/0100	514/944	1
US 6048855	USPAT	20000411	Topical composition	514/213.0	424/401	De Lacharriere;
A			containing capsazepine	1		Olivier et al.
US 6019967	USPAT	20000201	Therapeutic/cosmetic	424/130.1	424/401;	Breton; Lionel et
Α			compositions comprising		424/47;	al.
	1		CGRP antagonists for		424/489;	·
			treating sensitive human		424/70.1;	
			skin	.	514/2;	
					514/844;	
		,			514/846;	•
				ĺ	514/937;	
•					530/300;	
					530/387.1	
US 5993833	USPAT	19991130	· ·	424/401	424/70.1;	De Lacharriere;
Α			interleukin-1 antagonist		514/25;	Olivier et al.
			and/or a TNF alpha		514/263.31;	
			antagonist in a cosmetic,		514/339;	
			pharmaceutical or		514/352;	
			dermatological		514/382;	

	Į		composition	1	514/840;	T
					514/859;	
			,		514/937;	
					514/944	
US 5989568	USPAT	19991123	Cosmetic/dermatological	424/401	424/450;	Breton; Lionel
A			skin care compositions		424/489;	al.
•			comprising S-DHEA		514/844;	
			r		514/937;	·
			t .		514/944	
US 5976559	USPAT	19991102	Compositions and	424/401	514/844;	De Lacharriere;
A	}		methods for treating		514/846;	Olivier et al.
	[wrinkles and/or fine lines		514/944	
			of the skin			
US 5972892	USPAT	19991026	Topical composition	514/15	514/210.01;	De Lacharriere
A			containing a substance P		514/293;	Olivier et al.
			antagonist		514/305;	
					514/315;	
					514/410;	
					514/416;	
		,			514/422;	
••					514/423;	
			,		514/426;	
					514/438;	
					514/461;	
					514/613;	1
•					514/617;	
					514/646;	
			251.5116.6.1.11		514/663	
US 5958432	USPAT	19990928	Cosmetic/pharmaceutical	424/401	424/450;	Breton; Lionel
A			compositions comprising		424/451;	al.
			betaadrenergic		424/464;	1
			agonists/substance P		424/47;	
	{		antagonists		424/489;	
	ľ				424/49;	1
				1	424/701;	
					514/844;	
					514/845;	
					514/846;	
					514/847;	
					514/861;	
					514/863;	
			·		514/885;	
			·		514/903;	
11.			. ,		514/912;	
					514/944	1 .
US 5935586	USPAT	19990810	Therapeutic/cosmetic	424/401	424/130.1;	De Lacharriere
A			compositions comprising		424/139.1;	Olivier et al.
			CGRP antagonists for		424/198.1;	
				•		
		•			•	

			treating disease states of		424/450;	
			the skin		424/451;	
			the skin		424/490;	
			*		514/2	
110 5022215	LICDATE	1000000	TCI 4' / 4'	424/150.1		1. T 1
US 5932215	USPAT	19990803	Therapeutic/cosmetic	424/158.1	424/130.1;	de Lacharriere;
A	1		compositions comprising	•	424/133.1;	Olivier et al.
			CGRP antagonists for		424/145.1;	
•			treating skin	·	424/185.1;	
		•	redness/rosacea/discrete		424/198.1;	
			erythema		424/401;	
	1	l	-16-		424/809;	
] '		·		514/2	
US 5902805	USPAT	19990511	Method for treatment of	514/159	424/401;	Breton; Lionel et
A			ache and/or the effects of		514/161;	al.
			ageing using HMG-		514/460;	
			coenzyme A-reductase		514/844;	
			inhibitor and		514/845;	
			compositions for		514/847;	
			performing the same		514/848;	
			P		514/852;	
					514/859;	
	·		·		514/861;	
			·		514/863;	
					514/887;	
					514/969	
US 5900257	USPAT	19990504	Cosmetic/pharmaceutical	424/639	424/600;	Breton; Lionel et
	USIAI	19990304	compositions comprising	424/039	424/617;	al.
Α			, , , ,		424/617,	ai.
			lanthanide manganese, tin		1	
	,		and/or yttrium salts as		424/650;	
·			substance P antagonists		424/677;	
					424/715;	
					424/718;	
				10.11101	424/722	
US 5900242	USPAT	19990504	Cosmetic/dermatological	424/401	424/450;	Breton; Lionel et
Α			skin care compositions		424/489;	al.
			comprising S-DHEA		514/844;	
					514/937;	
					514/944	
US 5895649	USPAT	19990420	Method for treating	424/130.1	424/520;	De Lacharriere;
A			neurogenic red skin		424/725;	Olivier et al.
			blotches with		424/764;	
			compositions containing		514/2;	
		· 1	TNF-alpha antagonists		514/263.31;	
					514/338;	
					514/557;	
					514/588;	
					514/738;	

. *						
·					514/887; 514/937; 514/938	
US 5869068 A	USPAT	19990209	Compositions and methods for treating wrinkles and/or fine lines of the skin	424/401	514/844; 514/846; 514/944	De Lacharriere; Olivier et al.
US 5866168 A	USPAT	19990202	Dermatological/pharmace utical compositions comprising lanthanide, manganese, tin, zinc, yttrium, cobalt, barium and/or strontium salts as substance P antagonists	424/639	424/600; 424/617; 424/646; 424/650; 424/677; 424/715; 424/718; 424/722	De Lacharriere; Olivier et al.
US 5858024 A	USPAT	19990112	Composition for dyeing keratin fibres containing a substance P antagonist	8/408	424/70.6; 8/405; 8/406; 8/407; 8/423; 8/563; 8/618; 8/637.1	De Lacharriere; Olivier et al.
US 5851556 A	USPAT	19981222	Use of a salt of an alkaline-earth metal as TNF-A or substance P inhibitor in a topical composition and composition obtained	424/639	424/600; 424/617; 424/646; 424/650; 424/677; 424/715; 424/718; 424/722	Breton; Lionel et al.
US 5849312 A	USPAT	19981215	Therapeutic/cosmetic compositions comprising bradykinin antagonist for treating sensitive human skin	424/401	424/43; 424/489; 424/49; 424/70.1; 514/844; 514/936; 514/944	Breton; Lionel et al.
US 5824650 A	USPAT	19981020	Topical composition containing a substance P antagoinst	514/15	514/167; 514/210.03; 514/252.04; 514/293; 514/305; 514/315; 514/410; 514/416; 514/422; 514/423; 514/426; 514/438;	De Lacharriere; Olivier et al.

			· · · · · · · · · · · · · · · · · · ·		514/461;	
					514/401,	
					514/617;	
					514/646;	
·					514/663	
US 5803095	USPAT	19980908	Permanent wave	132/204	132/200;	De Lacharriere;
A	051711	17700700	compositions comprising	152/201	132/200;	Olivier et al.
			substance P/CGRP		132/203;	
			antagonists		424/70.2	
US 5795574	USPAT	19980818	Use of an extract from a	424/115	424/158.1;	Breton; Lionel et
Α			non-photosynthetic		424/617;	al.
			filamentous bacterium and		424/630;	
•			composition containing it		424/639;	·
					424/641;	
					424/642;	,
					424/646;	
					424/650;	
					424/681;	
			4		424/74;	
					514/15;	
					514/17;	
					514/183;	·
			*		514/44;	
					514/443;	
	ļ			12.115.7	514/783	
US 5788956	USPAT	19980804	Antiperspirant	424/65	424/400;	De Lacharriere;
Α .			compositions comprising		424/401;	Olivier et al.
			substance P antagonists		424/404;	
					424/66;	
					424/67; 424/68	
110 5744156	LICDAT	10000420	Use of a substance P	424/445	424/68	De Lacharriere;
US 5744156	USPAT	19980428	antagonist for the	424/443	424/443	Olivier et al.
Α .			treatment of skin			Olivici ci ai.
			reddening of neurogenic			
			origin			
US 5733558	USPAT	19980331	Method for treatment of	424/401	514/159;	Breton; Lionel et
A	OBLAT	1,7,00331	acne and/or the effects of	12 1/ 101	514/460;	al.
4.			ageing using HMG-		514/852;	""
			coenzyme A-reductase		514/863	÷
		1	inhibitor and			
			compositions for			,
			performing the same			
US 5730998	USPAT	19980324	Use of a substance P	424/443	424/423;	de Lacharriere;
Α			antagonist for the		424/451;	Olivier et al.
			treatment of pruritus,		424/464	
	,		ocular and/or palpebral		1 .	
			pain and ocular or	<u> </u>	·	
•						

			palpebral dysaesthesia			
US 5714155	USPAT	19980203	Ethylenediamine	424/401	514/844;	De Lacharriere;
A			derivative in a cosmetic or		514/846;	Olivier et al.
			dermatological		514/937;	
			composition, and		514/938;	
			composition containing in	·	514/944	
			particular a product			
			having an irritant side		·	
			effect			
US 5679360	USPAT	19971021	Substance P antagonist for	424/401	424/434;	de Lacharriere;
A			the treatment of lichens,		424/436;	Olivier et al.
			prurigo, pruritus		424/450;	
					424/489;	
					514/2;	
					514/844;	
		-			514/937;	
					514/944	
US 5658581	USPAT	19970819	Histamine antagonist, an	424/401	424/701;	De Lacharriere;
A		•	interleukin-1 antagonist		514/840;	Olivier et al.
	Υ		and/or a TNF alpha		514/859;	
'			antagonist in a cosmetic,		514/937;	
			pharmaceutical or		514/944	
			dermatological			
			composition and			
			composition obtained			

. •